Перспективы фармакотерапии ревматоидного артрита: моноклональные антитела

1. <div><p>Taylor P.C., Feldman M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 2009;5:578-82.</p><p>Feldman M., Maini R. Anti-TNF therapy, from rationale to standart of care: what lessons has it taught us. J Immunol 2010;185(2):791-4.</p><p>Van Vollenhoven R.F. Unresolved issues in biologic therapy for rheumatoid arthritis. Nat Rev Rheumatol 2011;7:205-15.</p><p>Autoimmunity treatment (2009-2011). www.reportlinker.com</p><p>St Clair E.W. Novel targeted therapies for autoimmunity. Curr Opin Immunol 2009;21:648-57.</p><p>Genovese M.C., Covarrubias A., Leon G. et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with inadequate response to methotrexate. Arthr Rheum 2011;63:2854-64.</p><p>Corbo M., Valencia X., Raymond R. et al. Subcutaneous administration of abatacept in patients with rheumatoid arthritis: pharmacokinetics, safety and immunogenecity. Ann Rheum Dis 2009;68(Suppl. 3):574.</p><p>Nash P., Nayiger S., Genovese M.C. et al. Low immunogenecity, consistent safety and sustained clinical efficacy over 18 months of subcutaneous (SC) administration of abatacept (ABA) with or without methotrexate in patients with rheumatoid arthritis (RA): results from a phase III study. Ann Rheum Dis 2010;69(Suppl. 3):97.</p><p>Kaine J., Gladstein G., Strusberg I. et al. Evaluation of abatacept administered subcutanously in adults with active rheumatoid arthritis: impacr of withdeawal and reintroduction on immunogenecity, efficacy and safety (Phase IIIb ALLOW study). Ann Rheum Dis 2012;71:38-44.</p><p>Keystone E.C., Kremer J.M., Russell A. et al. Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study. Ann Rheum Dis 2012;12 Feb.</p><p>Насонов Е.Л. Применение тоцилизумаба при ревматоидном артрите: новые данные. Науч-практич ревматол 2011;6:46-56.</p><p>Ohta S., Tsura T., Terao K. et al. Optimal dose prediction by pharmacokinetic and biomarker response of subcutaneous tocilizumab treatment: a phase I/II study evaluating the safety, pharmacokinetics and clinical response in patients with rheumatoid arthritis. Arthr Rheum 2010;62:S1115.</p><p>Shakib J., Sepehr F., Smith B. Safety, pharmacokinetics and pharmacodynamics of ALD518 (BMS-945429), a high-affinity monoclonal antibody directed against interleukin-6 (IL-6) administered by subcutaneous injection: a phase I trial. Arthr Rheum 2010;62(Suppl. 10):1124.</p><p>Mease P., Strand V., Shalamberidze L. et al. A phase II, doubleblind, randomized, placeb0-controlled study of BMS945429 (ADL518) in patients with rheumatoid arthritis with an inadequate respose to methotrexate. Ann Rheum Dis 2012;Feb 2012.</p><p>Strand V., Shalamberidze L., Dimic A. et al. BMS-945429 (ALD518), a high-affinity anti-interleukin-6 monoclonal antibody, is associated with improvements in health-related quality of life in patients with rheumatoid arthritis and inadequate response to methotrexate. Ann Rheum Dis 2011;70(Suppl. 3):621.</p><p>Taub R. Hepatoprotection via the IL-6/Stat3 pathway. J Clin Invest 2003;112:978-80.</p><p>ClinicalTrials.gov. Phase IIB rheumatoid arthritis dose ranging study for BMS-945429 in subjects who are not responding to methotrexate. 2011. Accessed 10/21/11 at: http://clinicaltrials.gov/ct2/show/NCT01373151</p><p>Sanofi and Regeneron report positive phase 2b trial results with sarilumab in rheumatoid arthritis [press release]. Paris, France, and Tarrytown, NY: PR Newswire; July 12, 2011. Accessed 10/21/11 at: http://www.reuters.com/article/2011/07/12/idUS215877+12-Jul 2011+PRN20110712</p><p>Radin A.R., Mellis S.J., Jasson M. et al. REGN88/SAR153191, a fully-human interleukin-6 receptor monoclonal antibody, reduced acute phase reactants in patients with rheumatoid arthritis: preliminary observations from phase 1 studies. Arthr Rheum 2010;S1121.</p><p>ClinicalTrials.gov. Evaluation of SAR153191 (REGN88) on top of methotrexate in rheumatoid arthritis patients (MOBILITY). 2011. Accessed 10/21/11 at: http://clinicaltrials.gov/ct2/show/NCT01061736</p><p>ClinicalTrials.gov. Effect of SAR153191 (REGN88) with methotrexate in patients with active rheumatoid arthritis who failed TNF-а blockers. 2011. Accessed 10/21/11 at: http://clinicaltrials.gov/ct2/show/NCT01217814</p><p>ClinicalTrials.gov. Long term evaluation of SAR153191 (REGN88) on top of disease modifying anti-rheumatic drugs in rheumatoid arthritis patients (ABILITY). 2011. Accessed 10/21/11 at: http://clinicaltrials.gov/ct2/show/NCT01146652</p><p>Xu Z., Bouman-Thio E., Comisar C. et al. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol 2011;72:270-81.</p><p>Hsu B., Zhou B., Smolen J.S., Weinblatt M.E. Proof-of-concept for CNTO 136, a human anti-interleukin-6 monoclonal antibody, in a multicenter, randomized, double-blind, placebo-controlled, phase 2 study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2011;70(Suppl. 3):459.</p><p>ClinicalTrials.gov. A study of the effectiveness and safety of CNTO 136 in patients with active rheumatoid arthritis despite methotrexate therapy. 2011. Accessed 10/21/11 at: http://clinicaltrials.gov/ct2/show/NCT00718718</p><p>Hickling M., Golor G., Jullion A. et al. Safety and pharmacokinetics of CDP6038, an anti-IL-6 monoclonal antibody, administered by subcutaneous injection and intravenous infusion to healthy male volunteers: a phase 1 study. Ann Rheum Dis 2011;70(Suppl. 3):471.</p><p>ClinicalTrials.gov. To evaluate the blood levels and safety of IV and subcutaneous CDP6038 in subjects with rheumatoid arthritis using methotrexate. 2010. Accessed 10/21/11 at: http://clinicaltrials.gov/ct2/show/NCT01009242</p><p>ClinicalTrials.gov. Open-label study to assess the safety and efficacy of CDP6038 in patients who completed RA0056. 2011. Accessed 10/21/11 at: http://clinicaltrials.gov/ct2/show/NCT01296711</p><p>ClinicalTrials.gov. Efficacy and safety of CDP6038 in patients with rheumatoid arthritis with an unsuccessful response to anti-tumor necrosis factor (anti-TNF) therapy. 2011. Accessed 10/21/11 at: http://clinicaltrials.gov/ct2/show/NCT01242488</p><p>Baker J.F., Bendit M.C., Campanile M. et al. A randomised, single-blind, placebo-controlled dose escalation study to investigate the safety, tolerability and pharmacokinetics of a single intravenous infusion of GSK315234 in healthy volunteers. Arthr Rheum 2009;60(Suppl. 10):427.</p><p>ClinicalTrials.gov. Phase II study evaluating the safety and efficacy of GSK315234 in patients with rheumatoid arthritis. 2011. Accessed 10/21/11 at: http://clinicaltrials.gov/ct2/show/NCT00674635</p><p>Fleischmann R., Sayiager S., Louw S. et al. A multiple ascending dose/proof of concept study of ATN-10-3 (ozoralizumab) in rheumatoid arthritis subjects on a Background of Methotrexate. Arthr Rheum 2011;63(Suppl. 10):2630.</p><p>ClinicalTrials.gov. Study evaluating multiple doses of ATN-103 in subjects with active rheumatoid arthritis. 2011. Accessed 10/21/11 at: http://www.clinicaltrials.gov/ct2/show/NCT00959036</p><p>ClinicalTrials.gov. Study evaluating long-term safety of ATN-103 in subjects with rheumatoid arthritis. 2011. Accessed 10/21/11 at: http://clinicaltrials.gov/ct2/show/NCT01063803</p><p>Moissec P., Korn T., Kuchroo V.K. Interleukin-17 and type 17 helper N cells. N Engl J Med 2009;361:888-98.</p><p>Lubbert E. IL17/Th17 targeting: on the road to prevebt chronic destructive arthritis? Cytokine 2008;41:84-91.</p><p>Durez P., Chindalore V., Wittmer B. et al. AIN457, an anti-IL-17 antibody, shows good safety and induces clinical responses in patients with active rheumatoid arthritis (RA) despite methotrexate therapy in a randomized double-blind proof-of-concept trial. Ann Rheum Dis 2009;68(Suppl. 3):iii125.</p><p>Genovese M., Durez P., Richards H. et al. Secukinumab (AIN457) showed a rapid decrease of disease activity in patients with active rheumatoid arthritis including those with high inflammatory burden. Abstract FRI0308. Presented at: EULAR Congress; May 25-28, 2011; London, England.</p><p>ClinicalTrials.gov. Efficacy at 24 weeks and safety, tolerability and long term efficacy up to 1 year of secukinumab (AIN457) in patients with active rheumatoid arthritis (RA) and an inadequate response to anti-tumor necrosis factor а (anti-TNF«) agents. 2011. Accessed 10/21/11 at: http://clinicaltrials.gov/ct2/show/NCT01350804</p><p>ClinicalTrials.gov. Efficacy at 24 weeks and safety, tolerability and long term efficacy up to 2 years of secukinumab (AIN457) in patients with active rheumatoid arthritis and an inadequate response to anti-TNF« agents. 2011. Accessed 10/21/11 at: http://clinicaltrials.gov/ct2/show/NCT01377012</p><p>ClinicalTrials.gov. Double blind, placebo-controlled, study of the safety, tolerability and pharmacokinetics of AIN457 in rheumatoid arthritis patients. 2010. Accessed 10/21/11 at: http://clinicaltrials.gov/ct2/show/NCT00669942</p><p>ClinicalTrials.gov. Double blind, placebo-controlled, study of the safety, tolerability and pharmacokinetics of AIN457 in rheumatoid arthritis patients. 2010. Accessed 10/21/11 at: http://clinicaltrials.gov/ct2/show/NCT00669942</p><p>ClinicalTrials.gov. Efficacy, safety and tolerability of secukinumab in patients with rheumatoid arthritis taking methotrexate. 2011. Accessed 10/21/11 at: http://www.clinicaltrials.gov/ct2/show/NCT01359943</p><p>Genovese M.C., van den Bosch F., Roberson S.A. et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthr Rheum 2010;62:929-39.</p><p>ClinicalTrials.gov. A study in patients with rheumatoid arthritis. 2011. Accessed 10/21/11 at: http://clinicaltrials.gov/ct2/show/NCT00966875</p><p>ClinicalTrials.gov. Multiple-dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of AMG 827 in subjects with rheumatoid arthritis. 2011. Accessed 10/21/11 at: http://www.clinicaltrials.gov/ct2/show/NCT00771030</p><p>ClinicalTrials.gov. AMG 827 in rheumatoid arthritis subjects with inadequate response to methotrexate. 2011. Accessed 10/21/11 at: http://www.clinicaltrials.gov/ct2/show/NCT00950989</p><p>Hamilton J.A. Colony-stimulating factors in inflammation and autoimmunity. Nar Rev Immunol 2008;8:533-44.</p><p>Burmester G.R., Feist E., Sleeman M.A. et al. Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor , in subjects with rheumatoid arthritis: a randomized, double-blind, placebo-controlled, phase I, first-in-human study. Ann Rheum Dis 2011;70:21542-9.</p><p>ClinicalTrials.gov. Study of KB003 in biologics-inadequate rheumatoid arthritis. 2011. Accessed 10/21/11 at: http://clinicaltrials.gov/ct2/show/NCT00995449</p><p>Szekanecz Z., Koch A.E., Tak P.P. Chemokine and chemokine receptor blockade in arthritis, a prototype of immune-mediated inflammatory disease. Ned J Med 2011;69:356-66.</p><p>Yellin M., Paliienko I., Balanescu A. et al. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthr Rheum 2011;23 Oct (on line).</p><p>Van Kuijk A.W., Vergunst C.E., Gerlag D.M. et al. CC5 blockade in rheumatoid arthritis: a randomized, double-blind, placebo-controlled clinical trial. Ann Rheum Dis 2010;69:2013-6.</p><p>Emy B., Luca D., Offutt C. et al. Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin: results of a phase I randomized, placebo-controlled trial. Arthr Res Ther 2012;14:R6.</p><p>Calmon-Hamaty F., Combe B., Hahne M., Morel J. Lymphotoxin a stimulates proliferation and pro-inflammatory cytokine secretion of rheumatoid arthritis synovial fibroblasts. Cytokine 2011;53:207-14.</p><p>Browning J.L. Inhibition of the lymphotoxin pathway as a therapy for autoimmune disease. Immunol Rev 2008;223;202-20.</p><p>ClinicalTrials.gov. A study to evaluate the efficacy and safety of MLTA3698A in combination with a disease-modifying anti-rheumatic drug (DMARD) compared with adalimumab in combination with a DMARD in patients with active rheumatoid arthritis. 2011. Accessed 10/21/11 at: http://clinicaltrials.gov/ct2/show/NCT01225393</p><p>Baldassare A., Fiechtner J., Filipowicz-Sosnowska A. et al. Preliminary safety and efficacy of baminercept alfa (BG9924, LTBR-IG) in the treatment of rheumatoid arthritis (RA). Ann Rheum Dis 2008;67(Suppl. 2):86.</p><p>Genovese M.C., Greenwald M.W., Alloway J.A. et al. Efficacy and safety of baminercept in the treatment of rheumatoid arthritis (RA) results of the phase 2B study in the TNF-IR population. Arthr Rheum 2009;60(Suppl. 10):417.</p><p>ClinicalTrials.gov. BG9924 in combination with methotrexate for subjects with active rheumatoid arthritis. 2009. Accessed 10/21/11 at: http://clinicaltrials.gov/ct2/show/NCT00458861</p><p>Boumans M.J.H., Houibers J.G.A., Verschueren P. et al. Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomized, placebo controlled, proof-of-concept study. Ann Rheum Dis 2012;71:180-5.</p><p>Schett G. Cells of the synovium in rheumatoid arthritis. Arthr Res Ther 2007;9:203.</p><p>Gabay C., Lamacchia C., Palmer G. IL-1 pathway in inflammation and human diseases. Nat Rev Rheumatol 2010;6:232-41.</p><p>Ильина А.Е., Станислав М.Л., Денисов Л.Н., Насонов Е.Л. Интерлейкин 1 как медиатор воспаления и терпапевтическая мишень. Науч-практич ревматол 2011;1:62-71.</p><p>Dayer J.M. The pivotal role of interleukin 1 in the clinical manifestations of rheumatoid arthritis. Rheumatology 2003;42(Suppl. 2):ii3-10.</p><p>Mertens M., Singh J. Anakinra for rheumatoid arthritis. Cochrane Database of Systemic Review 2009;1:CD005121.</p><p>Alten R., Gram H., Joosten L.A. et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammatory models in mice and a proof-of-concept study in patients with rheumatoid arthritis. Arthr Res Ther 2008;10:67.</p><p>Alten R., Gomwz-Reino J., Durez P. et al. Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis:results of a 12-week, phase II, dose-finding study. BMC Musculoskeletal Dis 2011;12:153.</p><p>Dhimolea E. Canakinumab. mAbs 2010;2:3-13.</p><p>Van der Kolk L.E., Grilo-Lopez A.J., Baars J.W. et al. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001;115:897-911.</p><p>Genovese M.C., Kaine J.L., Lowenstein M.B. et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthr Rheum 2008;58:2652-61.</p><p>Stohl W., Gomez-Reino J., Olech E. et al. Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase II FILM trial. Ann Rheum Dus 2012, Feb 2.</p><p>Rigby W., Tony H.-P., Oelke K. et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an Inadequate response to methotrexate. The phase III STAGE Trial. Arthr Rheum 2012;64:350-9.</p><p>Tak P.P., Mease P.J., Genovese M.C. et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and inadequate response to at least one tumor necrosis factor inhibitor. Arthr Rheum 2012;64:360-70.</p><p>Lin T.S. Ofatumumab: a novel monoclonal anti-CD20 antibody. Pharmacogenom Personoliz Med 2010;3:51-9.</p><p>Ostergaard M., Baslund B., Rigby W. et al. Ofatumamab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthr Rheum 2010;62:2227-38.</p><p>Taylor P.C., Quattrocchi E., Mallett S. et al. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biologically-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomized, double-blind, placebo-controlled clinical trial. Ann Rheum Dis 2011;Aug 22.</p><p>Dorner T., Radbruch A., Burmester G.R. B-cell-directed therapies fo autoimmune disease. Nat Rev Rheumatol 2009 (on line).</p><p>Cancro M.P. The DLyS/BAFF family of ligand and receptor: key targets in the therapy and understanding of autoimmunity. Ann Rheum Dis 2006;65(Suppl. III):iii34-iii36.</p><p>Cheema G.S., Roschke V., Hilbert D.M. et al. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthr Rheum 2001;44:1313-9.</p><p>Tan S.M., Xu D., Roschke V. et al. Local production of B lymphocyte stimulator protein and APRIL in arthritis joints of patients with inflammatory arthritis. Arthr Rheum 2003;48:982-92.</p><p>Tak P.P., Thurling R.M., Rossier C. et al. Atacicept in patients with rheumatoid arthritis: results of a milticenter, phase Ib, double-blind, placebo-controlled, dose escalation, single- and repeated-dose study. Arthr Rheum 2008;58:61-72.</p><p>Nestorov I., Munafo A., Papasouliotis O., Visich J. Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis. J Clin Pharmacol 2008;48:406-17.</p><p>Van Vollenhoven R.F., Kinnman N., Vincent E. et al. Atacicept in patients with rheumatoid arthritis and inadwquate response to methotrexate: results of a phase II, randomized placebo-controlled trial. Arthr Rheum 2010;Sept 28.</p><p>Ding C. Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases. Exp Opin Biol Ther 2008;8:1805-15.</p><p>Genovese M., Filipowicz-Sosnovska A., Merrill J. et al. Differential responsiveness to belimumab (BmAb) in combination with standart of care threrapy in RF+, TNF -inhibitor and methotrexate partial responder subgroups of subjects with moderate-severe rheumatoid arthritis. Arthr Rheum 2005;59:S738.</p><p>McKay J., Chwalinska-Sadowska H., Boling E. et al. Belimumab (BmAb). A fully human monoclonal antibody to B-lymohocyte stimulator (BLyS), combined with standart care therapy reduced the singh and vsymptoms of rheumatoid arthritis. In a heterogenous subject population. Arthr Rheum 2005;52:S710-S711.</p><p>Stohl W., Chatham W., Weisman M. et al. Belimumab (BmAb), a novel fully human monoclonal antibody to B-lymphocyte stimultor (BLyS), selectively modulates B-cell subpopulations and immunoglobulins in the heterogenous rheumatoid arthritis subjects population. Arthr Rheum 2005;51:S444.</p><p>Genovese M.C., Bojin S., Biagini M. et al. Effects on B cells, safety and efficacy of LY2127399, a novel anti-BAFF MAB, in patients with active rheumatoid arthritis. Abstract OP0052. Presented at: EULAR Congress; June 16-19, 2010; Rome, Italy.</p><p>ClinicalTrials.gov. A study for patients with active rheumatoid arthritis despite ongoing methotrexate therapy. 2011. Accessed 10/21/11 at: http://clinicaltrials.gov/ct2/show/NCT00785928</p><p>ClinicalTrials.gov. A rheumatoid arthritis study in patients on a background treatment of methotrexate (FLEX M). 2011. Accessed 10/21/11 at: http://www.clinicaltrials.gov/ct2/show/NCT01198002</p><p>ClinicalTrials.gov. A rheumatoid arthritis study in patients (FLEX O). 2011. Accessed 10/21/11 at: http://www.clinicaltrials.gov/ct2/show/NCT01202760</p><p>ClinicalTrials.gov. A study in patients with rheumatoid arthritis (FLEX V). 2011. Accessed 10/21/11 at: http://www.clinicaltrials.gov/ct2/show/NCT01202773</p><p>ClinicalTrials.gov. An open label study for patients with rheumatoid arthritis. 2011. Accessed 10/21/11 at: http://www.clinicaltrials.gov/ct2/show/NCT01215942</p></div><br />